349 related articles for article (PubMed ID: 28362316)
21. Molecular signaling involving intrinsically disordered proteins in prostate cancer.
Russo A; Manna SL; Novellino E; Malfitano AM; Marasco D
Asian J Androl; 2016; 18(5):673-81. PubMed ID: 27212129
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
23. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy.
Faramarzi S; Ghafouri-Fard S
Immunotherapy; 2017 Sep; 9(12):1019-1034. PubMed ID: 28971747
[TBL] [Abstract][Full Text] [Related]
24. Expression of Cancer-Testis Antigens in Pediatric Cancers.
Ghafouri-Fard S
Asian Pac J Cancer Prev; 2015; 16(13):5149-52. PubMed ID: 26225644
[TBL] [Abstract][Full Text] [Related]
25. The role of Cancer/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy.
Shires K; Van Wyk T
Crit Rev Oncol Hematol; 2018 Dec; 132():17-26. PubMed ID: 30447924
[TBL] [Abstract][Full Text] [Related]
26. Cancer/testis antigens trigger epithelial-mesenchymal transition and genesis of cancer stem-like cells.
Yang P; Huo Z; Liao H; Zhou Q
Curr Pharm Des; 2015; 21(10):1292-300. PubMed ID: 25506890
[TBL] [Abstract][Full Text] [Related]
27. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
[TBL] [Abstract][Full Text] [Related]
28. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
29. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
30. Cancer-testis antigens in canine histiocytic sarcoma and other malignancies.
Nemec PS; Kapatos A; Holmes JC; Stowe DM; Hess PR
Vet Comp Oncol; 2019 Sep; 17(3):317-328. PubMed ID: 30854786
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins.
Mooney SM; Jolly MK; Levine H; Kulkarni P
Asian J Androl; 2016; 18(5):704-10. PubMed ID: 27427552
[TBL] [Abstract][Full Text] [Related]
32. PAGE4 and Conformational Switching: Insights from Molecular Dynamics Simulations and Implications for Prostate Cancer.
Lin X; Roy S; Jolly MK; Bocci F; Schafer NP; Tsai MY; Chen Y; He Y; Grishaev A; Weninger K; Orban J; Kulkarni P; Rangarajan G; Levine H; Onuchic JN
J Mol Biol; 2018 Aug; 430(16):2422-2438. PubMed ID: 29758263
[TBL] [Abstract][Full Text] [Related]
33. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
34. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
[TBL] [Abstract][Full Text] [Related]
35. Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer.
Nin DS; Deng LW
Cells; 2023 Mar; 12(6):. PubMed ID: 36980267
[TBL] [Abstract][Full Text] [Related]
36. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.
Mathieu R; Evrard B; Fromont G; Rioux-Leclercq N; Godet J; Cathelineau X; Guillé F; Primig M; Chalmel F
Prostate; 2013 Jul; 73(10):1103-14. PubMed ID: 23532770
[TBL] [Abstract][Full Text] [Related]
37. The therapeutic potential value of Cancer-testis antigens in immunotherapy of gastric cancer.
Alsadat Mahmoudian R; Amirhosein M; Mahmoudian P; Fardi Golyan F; Mokhlessi L; Maftooh M; Khazaei M; Nassiri M; Mahdi Hassanian S; Ghayour-Mobarhan M; Ferns GA; Shahidsales S; Avan A
Gene; 2023 Feb; 853():147082. PubMed ID: 36464170
[TBL] [Abstract][Full Text] [Related]
38. Cancer/testis antigens: from serology to mRNA cancer vaccine.
Fan C; Qu H; Wang X; Sobhani N; Wang L; Liu S; Xiong W; Zeng Z; Li Y
Semin Cancer Biol; 2021 Nov; 76():218-231. PubMed ID: 33910064
[TBL] [Abstract][Full Text] [Related]
39. Protein conformational dynamics and phenotypic switching.
Kulkarni P; Achuthan S; Bhattacharya S; Jolly MK; Kotnala S; Leite VBP; Mohanty A; Orban J; Roy S; Rangarajan G; Salgia R
Biophys Rev; 2021 Dec; 13(6):1127-1138. PubMed ID: 35059032
[TBL] [Abstract][Full Text] [Related]
40. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
